Bristol-Myers Squibb Newsroom

Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $53

Moomoo News17:31 ET

Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $56 From $55, Maintains Neutral Rating

MT NewswiresApr 25 11:15 ET

Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $53 From $62, Maintains Equalweight Rating

MT NewswiresApr 25 11:15 ET

Bristol-Myers Squibb (BMY) Receives a Hold From Argus Research

TipRanksApr 25 09:49 ET

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Ironwood Pharma (IRWD) and Repligen (RGEN)

TipRanksApr 25 09:03 ET

Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $62

Moomoo NewsApr 25 04:31 ET

JPMorgan Cuts Price Target on Bristol-Myers Squibb to $67 From $70

MT NewswiresApr 24 14:39 ET

TD Cowen Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $64

Moomoo NewsApr 24 09:31 ET

William Blair Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating

Moomoo NewsApr 24 09:31 ET

Research Alert: Better Than Anticipated Q1 2025 Results While Cobenfy Trial Disappoints

MT NewswiresApr 24 08:55 ET

Bristol-Myers Squibb (BMY) Receives a Hold From TD Cowen

TipRanksApr 24 08:31 ET

Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $62

Moomoo NewsApr 24 04:33 ET

Optimistic Buy Rating for Bristol-Myers Squibb Amid Low Valuation and Promising Pipeline

TipRanksApr 24 02:48 ET

Citigroup Adjusts Bristol-Myers Squibb Price Target to $51 From $55

MT NewswiresApr 23 08:53 ET

Jefferies Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $68

BenzingaApr 23 08:48 ET

Bristol-Myers Squibb Analyst Ratings

BenzingaApr 23 08:47 ET

Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)

TipRanksApr 23 07:39 ET

Deutsche Bank Adjusts Bristol-Myers Squibb Price Target to $51 From $53, Maintains Hold Rating

MT NewswiresApr 23 07:31 ET

Bristol-Myers Squibb: Hold Rating Amid Clinical Challenges and Growth Uncertainty

TipRanksApr 23 07:21 ET

Hold Rating for Bristol-Myers Squibb's Cobenfy Amidst Uncertainties and Potential in Adjunctive Use for Schizophrenia

TipRanksApr 23 06:22 ET